A Randomized Controlled Trial of D-Cycloserine Enhancement of Exposure Therapy for Social Anxiety Disorder

School of Psychology, University of New South Wales, Sydney, Australia.
Biological psychiatry (Impact Factor: 9.47). 04/2008; 63(6):544-9. DOI: 10.1016/j.biopsych.2007.11.011
Source: PubMed

ABSTRACT Pilot research has suggested that D-cycloserine (DCS) enhances treatment outcomes for anxiety disorders when employed as an adjunct to exposure therapy (ET). The aim of this study was to determine whether 50 mg of DCS enhances ET for social anxiety disorder (SAD) according to a comprehensive set of symptom and life impairment measures.
In a randomized double-blind placebo-controlled trial, we administered 50 mg of DCS or placebo in combination with ET to 56 participants who met primary diagnosis for SAD.
Participants administered DCS reported greater improvement on measures of symptom severity, dysfunctional cognitions, and life-impairment from SAD in comparison with placebo-treated participants. Effect sizes were mostly in the medium range. Results also indicated that the amount of adaptive learning about one's ability to give speeches in front of an audience interacted with DCS to enhance treatment outcome.
This study shows that the administration of DCS before ET enhances treatment outcomes for SAD. Results also provide the first preliminary evidence to suggest that DCS moderates the relationship between a reduction in negative appraisals about one's speech performance and improvement in overall SAD symptoms.

Download full-text


Available from: Mark R Dadds, Jul 07, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical studies in adults and children with obsessive–compulsive disorder (OCD) have shown that d-cycloserine (DCS) can improve treatment response by enhancing fear extinction learning during exposure-based psychotherapy. Some have hypothesized that improved treatment response is a function of increased compliance and engagement in therapeutic homework tasks, a core component of behavioral treatment. The present study examined the relationship between DCS augmented cognitive-behavioral therapy (CBT) and homework compliance in a double-blind, placebo controlled trial with 30 youth with OCD. All children received 10 CBT sessions, the last seven of which included exposure and response prevention paired with DCS or placebo dosed 1 h before the session started. Results suggested that DCS augmented CBT did not predict improved homework compliance over the course of treatment, relative to the placebo augmented CBT group. However, when groups were collapsed, homework compliance was directly associated with treatment outcome. These findings suggest that while DCS may not increase homework compliance over time, more generally, homework compliance is an integral part of pediatric OCD treatment outcome.
    Journal of Child and Family Studies 07/2014; 23(5). DOI:10.1007/s10826-013-9742-1 · 1.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: La evaluación de la ansiedad social por medio de medidas de autoinforme suele utilizar alguno de los cuestionarios ampliamente conocidos a nivel internacional: el SPAI, la LSAS-SR, el SPIN, la SPS y/o la SIAS. En el presente estudio dichos cuestionarios se han aplicado a estudiantes universitarios, prestando especial atención a su estructura factorial y, en menor medida, a su fiabilidad y a su consistencia interna. Las mejores soluciones factoriales para estas medidas han sido las siguientes: para el SPAI, seis factores, para la subescala de ansiedad de la LSAS-SR, cinco factores, para el SPIN, tres factores, para la SPS, tres factores y para la SIAS, tres factores. La fiabilidad y la consistencia interna de estos cuestionarios son adecuadas. Se han comparado las diferentes soluciones obtenidas por los distintos cuestionarios y se ha realizado un análisis crítico de su estructura factorial a la luz de la estructura dimensional de la ansiedad social establecida por una nueva medida de autoinforme, el “Cuestionario de ansiedad social para adultos” (CASO-A30). Finalmente, se ha planteado la relevancia de estos análisis para una evaluación más eficiente de la ansiedad social tanto a nivel de la población general como a nivel clínico.
    Behavioral Psychology/Psicologia Conductual 12/2013; 21(3):423-448. · 0.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Viewing PTSD as a disorder of emotional learning, this study used a cognitive-enhancer synergistically with virtual reality exposure therapy (VRE) for the treatment of PTSD. The main objective was to determine if a novel pharmacotherapy, D-cycloserine (DCS), enhanced the efficacy of the psychotherapy. Pre-clinical studies suggest that when fear extinction occurs during DCS administration, neuroplasticity may be enhanced. VRE therapy is a particularly promising format to test the hypothesis that DCS enhances extinction learning, as sensory fear cues are standardized across patients. In a pilot randomized, double-blind, placebo controlled trial, 100 mg of DCS or placebo was administered 90 min before each weekly VRE session, to ensure peak plasma concentrations during the sessions, in 25 patients with chronic PTSD. The primary outcome measure was the Clinician Administered PTSD Scale (CAPS). Secondary outcome measures included the Beck Depression Inventory-II and the State-Trait Anger Expression Inventory-2. Assessments occurred at: pretreatment, following sessions 3, 6, 10, posttreatment, and at six-months. The difference in CAPS between the VRE-DCS (n=13) and VRE-placebo (n=12) groups increased over time beginning at six weeks, with medium to large between-group effect sizes immediately posttreatment and six months later (d=0.68 and d=1.13, respectively). A similar pattern was observed for depression, anger expression, and sleep. PTSD remission rates were significantly greater for the VRE-DCS group (46% vs 8% at posttreatment; 69% vs 17% at six-months). Patients in the VRE-DCS group showed earlier and greater improvement in PTSD symptoms compared to the VRE-placebo group. These results suggest a promising new treatment for PTSD.Neuropsychopharmacology accepted article preview online, 12 November 2013. doi:10.1038/npp.2013.317.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 11/2013; 39(5). DOI:10.1038/npp.2013.317 · 7.83 Impact Factor